Skip to main content
Clinical Trials/NCT04832659
NCT04832659
Active, not recruiting
Not Applicable

Assessment of Biomarkers in Children to Help Parents Quit Tobacco

Massachusetts General Hospital2 sites in 1 country865 target enrollmentJanuary 20, 2023
InterventionsCEASECEASE + BIO

Overview

Phase
Not Applicable
Intervention
CEASE
Conditions
Tobacco Dependence
Sponsor
Massachusetts General Hospital
Enrollment
865
Locations
2
Primary Endpoint
Parental quit rate
Status
Active, not recruiting
Last Updated
12 days ago

Overview

Brief Summary

This randomized controlled trial will test whether adding biomarker measurement and informed outreach for tobacco smoke exposure as part of routine practice increases identification and improves treatment, effectiveness, and sustainability of a parental tobacco control intervention that will be integrated into pediatric practice.

Detailed Description

This trial will examine the effectiveness of systematic cotinine testing of children 12 years old or younger using blood already collected at any visit to a practice that sees pediatric patients where there is a clinically indicated blood draw. We hypothesize that providing cotinine biomarker results to pediatricians, personalized cotinine feedback to parents about their child's toxin exposure, and offering support to all household tobacco users to quit tobacco use (Biomarker Informed Outreach (BIO)) when added to the Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention will increase delivery of tobacco cessation assistance, increase household cessation, reduce tobacco smoke exposure in children, and be cost-effective. This is a 2-arm randomized controlled trial with family-level randomization to either CEASE+BIO or CEASE arms at the time of the child's baseline visit. To compare the effectiveness of CEASE+BIO vs. CEASE, we will follow-up with enrolled parents 12 months later to assess parental quit rate and children's tobacco smoke exposure.

Registry
clinicaltrials.gov
Start Date
January 20, 2023
End Date
June 1, 2026
Last Updated
12 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jonathan P. Winickoff, MD, MPH

Professor

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Child 12 years old or younger presenting for a visit.
  • Child scheduled for or has had a clinically indicated blood draw at that visit
  • Parent/legal guardian of the child.
  • Parent/legal guardian is a current smoker (past 7 days).

Exclusion Criteria

  • Parent/legal guardian is non-English speaking.
  • Parent/legal guardian is less than 18 years of age.

Arms & Interventions

CEASE

Those assigned to the Active Comparator arm will receive the CEASE intervention.

Intervention: CEASE

CEASE + BIO

Those assigned to the Experimental CEASE + BIO arm will receive the CEASE intervention plus Biomarker Informed Outreach (BIO).

Intervention: CEASE

CEASE + BIO

Those assigned to the Experimental CEASE + BIO arm will receive the CEASE intervention plus Biomarker Informed Outreach (BIO).

Intervention: CEASE + BIO

Outcomes

Primary Outcomes

Parental quit rate

Time Frame: 12 months

Parental 7-day point-prevalence tobacco abstinence at 12-month follow-up, biochemically confirmed (corrected for NRT use)

Parental quit rate

Time Frame: 12 months

Parental 7-day point-prevalence tobacco abstinence at 12-month follow-up, biochemically confirmed (corrected for NRT use)

Secondary Outcomes

  • Self-report parental 7-day point prevalence tobacco abstinence(12 months)

Study Sites (2)

Loading locations...

Similar Trials